| Drug Type Small molecule drug | 
| Synonyms YY 201, YY-201, YY201 | 
| Target | 
| Action inhibitors | 
| Mechanism STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Acute Promyelocytic Leukemia | Phase 1 | China  | 26 Oct 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | China  | 26 Oct 2023 | |
| Chronic phase chronic myeloid leukemia | Phase 1 | China  | 26 Oct 2023 | |
| Large Granular Lymphocytic Leukemia | Phase 1 | China  | 26 Oct 2023 | |
| Peripheral T-Cell Lymphoma | Phase 1 | China  | 26 Oct 2023 | |
| Primary Malignant Liver Neoplasm | Phase 1 | China  | 26 Oct 2023 | |
| Refractory acute myeloid leukemia | Phase 1 | China  | 26 Oct 2023 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | China  | 26 Oct 2023 | |
| Triple Negative Breast Cancer | Phase 1 | China  | 26 Oct 2023 | |
| Pancreatic Cancer | Phase 1 | China  | 26 Oct 2023 | 





